Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonlinear pharmacokinetics: clinical Implications.

T M Ludden1

  • 1University of Texas, Austin.

Clinical Pharmacokinetics
|June 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population pharmacokinetic meta-analysis with efavirenz.

International journal of clinical pharmacology and therapeutics·2003
Same author

Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia.

Journal of pharmacokinetics and pharmacodynamics·2002
Same author

Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers.

Journal of pharmacokinetics and pharmacodynamics·2001
Same author

Time-variant increase in methylprednisolone clearance in patients with acute respiratory distress syndrome: a population pharmacokinetic study.

Journal of clinical pharmacology·2001
Same author

Analyzing rich data using different methods provided by NONMEM: pharmacokinetics of telmisartan following intravenous infusion to healthy volunteers.

Pharmaceutical research·1999
Same author

Balanced designs in longitudinal population pharmacokinetic studies.

Journal of clinical pharmacology·1998
Same journal

Population Pharmacokinetic Modelling of Dolutegravir: A Narrative Review.

Clinical pharmacokinetics·2026
Same journal

Partial Area Under the Curve: A Revelatory Story in Pharmacokinetics.

Clinical pharmacokinetics·2026
Same journal

Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model.

Clinical pharmacokinetics·2026
Same journal

Revisited Pharmacokinetic Profiles of Methylprednisolone in Plasma and Urine After Single and Multiple Oral Administrations: Relevance in Sports Drug Testing.

Clinical pharmacokinetics·2026
Same journal

ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma.

Clinical pharmacokinetics·2026
Same journal

Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer.

Clinical pharmacokinetics·2026
See all related articles

Nonlinear pharmacokinetics, where drug parameters change with time or dose, can result from absorption, metabolism, binding, or excretion issues. Understanding these nonlinearities is crucial for safe and effective drug dosing and therapeutic outcomes.

Area of Science:

  • Pharmacology
  • Drug Metabolism and Pharmacokinetics

Background:

  • Nonlinear pharmacokinetics arise from complex interactions in drug absorption, metabolism, distribution, and excretion.
  • Factors such as partial saturation of metabolic pathways, concentration-dependent binding, and autoinduction can lead to unpredictable drug concentrations.
  • These nonlinearities can significantly impact therapeutic efficacy and safety, necessitating careful consideration in drug development and clinical practice.

Purpose of the Study:

  • To elucidate the various mechanisms underlying nonlinear pharmacokinetics.
  • To highlight the clinical implications of nonlinear drug behavior.
  • To provide examples of drugs exhibiting nonlinear pharmacokinetic properties.

Main Methods:

  • Review of pharmacokinetic principles and mechanisms of nonlinearity.

Related Experiment Videos

  • Analysis of drug-specific examples illustrating different types of nonlinear behavior.
  • Discussion of the impact of nonlinearities on drug concentration-effect relationships.

    • Main Results:

    • Nonlinearities in absorption and bioavailability can cause disproportionate changes in drug concentrations relative to dose.
    • Partial saturation of presystemic metabolism (e.g., verapamil, propranolol) and elimination pathways (Michaelis-Menten kinetics, e.g., phenytoin, alcohol) are significant sources of nonlinearity.
    • Concentration-dependent drug binding (e.g., valproic acid) and autoinduction (e.g., carbamazepine) further contribute to complex pharmacokinetic profiles.
    • The presence of parallel linear pathways can influence steady-state concentrations and accumulation rates in drugs with saturable elimination (e.g., theophylline, salicylate).

    Conclusions:

    • Nonlinear pharmacokinetics, though observed in a minority of drugs, have significant clinical implications.
    • Accurate assessment and management of nonlinear drug behavior are essential for optimizing patient outcomes.
    • Further research into predicting and managing drug nonlinearities remains critical for advancing pharmacotherapy.